MT Newswires
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog
➖
AI Sentiment
Neutral
5/10
- Home
- BMY
as of 12-08-2025 3:43pm EST
$51.77
$0.33
-0.62%
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Chart Type:
Time Range:
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 95.0B | IPO Year: | N/A |
| Target Price: | $55.58 | AVG Volume (30 days): | 15.1M |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $42.52 - $63.33 | Next Earning Date: | 10-30-2025 |
| Revenue: | $48,034,000,000 | Revenue Growth: | 1.26% |
| Revenue Growth (this year): | 0.23% | Revenue Growth (next year): | -8.12% |
AI-Powered BMY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 80.13%
80.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Insider Monkey
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
➖
AI Sentiment
Neutral
5/10
Zacks
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
📈
AI Sentiment
Highly Positive
8/10
BioPharma Dive
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Bristol-Myers Says FDA Approves Breyanzi for Marginal Zone Lymphoma Treatment
📊
AI Sentiment
Positive
7/10
Business Wire
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Tigerlily Foundation Launches the "Bliss Collective: Brunch & Sip" Series to Empower, Educate, and Uplift Women Nationwide
📈
AI Sentiment
Highly Positive
9/10
Compare BMY vs Leading Stocks
See how BMY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.